Drug Targets for Cancer

Drug Targets for Cancer: Introduction

Since 1997, when the first targeted therapy drug was approved, targeted therapy has been a center in cancer therapy. The discovery of drug targets with effective methods and scientific tools has become vital and significant. Here are collections of drug targets for cancer and detailed collections for different kinds of cancers.

We provide proteins, antibodies, genes and ELISA kits of numerous drug targets to support your cancer research.

Drug Targets for Different Cancers

Drug Targets for Lung Cancer

Lung cancer, leading to the most cancer mortality, has been a popular researched disease. EGFR, ALK, VEGF/VEGFR, PDGF/PDGFR, PD1/PD-L1, ROS1, HER2 are the main targets in lung cancer research these years. Some monoclonal antibodies and small molecular inhibitors for these targets have been approved, which have shown distinctive efficacies in lung cancer therapy. More

Drug Targets for Breast Cancer

HER2 is the mostly researched target in breast cancer therapy, with two approved monoclonal antibody drugs and one small molecular inhibitor. CDK4/CDK6, affecting cell cycle, mTOR, functioning in cell apoptosis and VEGF-A, affecting angiogenesis are important targets in breast cancer therapy. More

Drug Targets for Ovarian Cancer

Bevacizumab has been approved for ovarian cancer as a VEGF-A targeted monoclonal antibody drug. Two inhibitors for PARP-1 have also been approved by affecting the DNA replication process in the therapy for ovarian cancer. More

Drug Targets for Colorectal Cancer

Two monoclonal antibody drugs targeting EGFR have been approved for the therapy of colorectal cancer. These drugs could function by influencing cell growth. Targeting angiogenesis is also a important strategy in colorectal cancer therapy, with two antibody drugs and one small molecular inhibitors have been approved. More

Drug Targets for Bladder Cancer

Immunotherapy plays an important role in the therapy of bladder cancer. Monoclonal antibodies targeting PD-1/PD-L1 pathway perform well in baldder cancer prognosis and have been approved by FDA. More

Drug Targets for Renal Cancer

Targeting raf signaling, angiogenesis, mTOR pathway, and PD-1 signaling are all improtant strategies in the therapy of renal cancer with approved drugs. More

Drug Targets for Leukemia Cancer

The oncoprotein BCR-ABL, membrane protein CD52 and CD20, BTK, affecting B-cell signaling, PI3Kδ, the key in PI3K/Akt signaling and BCL-2, functioning apoptosis are vital targets in the targeted therapy of Leukemia cancer. More

Drug Targets for Liver Cancer

The research progress in liver cancer therapy is slow. Most of the targted therapy is focused on PDGFR related angiogenesis. Hope more vital targets can be found to facilitate the development of liver cancer tharapy. More

Drug Targets for Lymphoma Cancer

Ubiquitin-proteasome system, Epigenetic related proteins, lymphocyte membrane proteins, cell growth signaling and B-cell receptor signaling are all important targets in the therapy of Lymphoma. More

Drug Targets for Pancreatic Cancer

Drug targets related with cell growth and angiogenesis are improtant in therapy of pancreatic cancer. More

Drug Targets for Prostate Cancer

Andrgen receptor is the main target in the therapy of prostate cancer. More

Drug Targets for Skin Cancer

Hedgehog pathway play a important role in the targeted therapy of skin cancer, SMO, a key protein in this progress, is a drug target for skin cancer. RAF/MEK/ERK signalling is a important target in the therapy with approved drugs. immune checkpoint PD-1 and CTLA-4 popular targets in skin cancer. More

Drug Targets for Thyroid Cancer

Some multi-targeted small molecular inhibitors targeting angiogenesis and cell growth have been approved for thyroid cancer. More

Drug Targets for Cancer: Related Information

Drug Targets and Cancer

Targeted therapy is an effective method for cancer, which shows instinct advantages over chemical therapy. The appropriate selection of drug targets is the key to the the success in cancer therapy. A common part of the targets are influencing cell growth and survival, and proliferation, and related to cell signalling pathways, such as EGFR, HER2, ALK, mTOR, RAF. Some of the drug targets are closely involved in pathological angiogenesis, such as VEGF/VEGFR, PDGFR, MEK. Recently, immune checkpoints have been hot targets in cancer therapy, especially, PD-1, PD-L1 and CTLA4, the monoclonal antibody drugs of these targets have performed great efficacies and deep potentials in the therapy of multiple cancers.